Center for Clinical Research : Active Breast Protocols           Study number links to NCI protocol site

Adjuvant

• B40 - Phase III Randomized Study of Six Different Neoadjuvant Chemotherapy Regimens With or Without Neoadjuvant and Adjuvant Bevacizumab in Women With Operable Stage I-IIIA

• IBCSG-2402- Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

• MA.17R - Phase III Randomized Study of Letrozole Versus Placebo in Postmenopausal Women With Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Aromatase Inhibitor

• S0221 - Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer

• S0307 - Phase III Randomized Study of Adjuvant Zoledronate Versus Clodronate Versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast

Early Stage

• B39 - Phase III Randomized Study of Adjuvant Whole Breast Versus Partial Breast Irradiation in Women With Ductal Carcinoma In Situ or Stage I or II Breast Cancer

Locally Advanced or Metastatic

• B37 - Phase III Randomized Study of Adjuvant Chemotherapy in Women With Radically Resected Loco-Regional Relapsed Breast Cancer

• N0337 - Phase II Study of Capecitabine, Vinorelbine, and Trastuzumab (Herceptin®) as First- or Second-Line Treatment in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer

• N0539 - SUSPENDED - Phase II Study of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor

• SO226 - Phase III Randomized Study of Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

• S0500 - Phase III Randomized Study of Treatment Decision Making Based on Levels of Circulating Tumor Cells in Women With Metastatic Breast Cancer Undergoing Chemotherapy

Node Negative

• PACCT1 - Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)

Node Positive

• CALGB-40101 - Phase III Randomized Study of Two Different Schedules of Adjuvant Cyclophosphamide and Doxorubicin Versus Paclitaxel in Women With Operable Breast Cancer and 0-3 Positive Axillary Lymph Nodes

• C70301 - Companion Study of Quality of Life, Employment, and Informal Care Costs in Women Receiving Adjuvant Chemotherapy for Breast Cancer With 0-3 Positive Axillary Lymph Nodes

Postmenopausal

• B42 - Phase III Randomized Study of Letrozole in Postmenopausal Women With Hormone Receptor-Positive Breast Cancer Who Have Completed Adjuvant Hormonal Therapy Comprising An Aromatase Inhibitor and/or Tamoxifen Citrate

• Z1031 - SUSPENDED - Phase III Randomized Study of Neoadjuvant Therapy Comprising Exemestane Versus Letrozole Versus Anastrozole in Postmenopausal Women With Estrogen Receptor Positive Stage II or III Breast Cancer

Quality of Life

• ECOG-E2ZO4 Quality of Life of Younger or Older Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance